MacroGenics (MGNX) Stock Price, News & Analysis

Company Overview

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.

Central to MacroGenics’ research platform are its ADAPTIR and Trident bispecific antibody technologies. The ADAPTIR platform enables the design of multi-specific antibodies with modular binding domains, allowing precise activation of immune cells. The Trident format supports the simultaneous targeting of three molecular entities, potentially improving selectivity and efficacy. These platforms underpin a diversified pipeline that spans oncology indications as well as immuno-oncology combinations and autoimmune disease targets.

Based in Rockville, Maryland, MacroGenics conducts its research and early development in the United States and collaborates with clinical trial centers across North America, Europe and Asia. Strategic partnerships with companies such as Merck, Servier and Kyowa Kirin have supported late-stage development, regulatory filings and potential commercialization in territories outside the United States. These alliances enhance the company’s ability to bring innovative therapies to a broader patient population.

Leadership at MacroGenics is headed by President and Chief Executive Officer Scott Koenig, who draws on extensive experience in oncology drug development to guide strategic and operational initiatives. The company’s governance is further strengthened by a scientific advisory board and an experienced management team, all of whom are committed to advancing novel antibody therapeutics through rigorous research and clinical evaluation.

Key Stats

• Today's Range: $1.65 to $1.75
• 50-Day Range: $1.44 to $2.00
• 52-Week Range: $0.99 to $5.10
• Volume: 343,476 shs
• Average Volume: 972,324 shs
• Market Capitalization: $104.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.60
• Consensus Rating: Moderate Buy

MacroGenics Stock Analysis - MarketRank™

MacroGenics scored higher than 89% of companies evaluated by MarketBeat, and ranked 110th out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

MacroGenics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.

Upside Potential

MacroGenics has a consensus price target of $3.60, representing about 116.9% upside from its current price of $1.66.

Amount of Analyst Coverage

MacroGenics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MacroGenics are expected to decrease in the coming year, from ($1.06) to ($2.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MacroGenics is -2.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MacroGenics is -2.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MacroGenics has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.48% of the float of MacroGenics has been sold short.

Short Interest Ratio / Days to Cover

MacroGenics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MacroGenics has recently decreased by 3.59%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MacroGenics does not currently pay a dividend.

Dividend Growth

MacroGenics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.61

Percentage of Shares Shorted

6.48% of the float of MacroGenics has been sold short.

Short Interest Ratio / Days to Cover

MacroGenics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MacroGenics has recently decreased by 3.59%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.40

News Sentiment

MacroGenics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for MacroGenics this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for MGNX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

4 people have added MacroGenics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, MacroGenics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $150,515.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

13.00% of the stock of MacroGenics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.89% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MGNX Stock Analysis - Frequently Asked Questions

How have MGNX shares performed this year?

MacroGenics' stock was trading at $3.25 on January 1st, 2025. Since then, MGNX stock has decreased by 48.9% and is now trading at $1.66.

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) posted its earnings results on Thursday, August, 14th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.02. The biopharmaceutical company earned $22.24 million during the quarter, compared to analyst estimates of $28.06 million. MacroGenics had a negative net margin of 21.99% and a negative trailing twelve-month return on equity of 40.24%.

Who are MacroGenics' major shareholders?

Top institutional investors of MacroGenics include Bellevue Group AG (15.72%), Armistice Capital LLC (9.45%), Acadian Asset Management LLC (3.95%) and EcoR1 Capital LLC (2.54%). Insiders that own company stock include Target N V Biotech, William K Heiden, Ezio Bonvini, Edward Hurwitz and Jeffrey Stuart Peters.
View institutional ownership trends.

How do I buy shares of MacroGenics?

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MacroGenics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MacroGenics investors own include NVIDIA (NVDA), Broadcom (AVGO), Invesco QQQ (QQQ), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and Jabil (JBL).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/23/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MGNX
• CIK: 1125345
• Web: www.macrogenics.com
• Phone: (301) 251-5172
• Fax: 301-251-5321
• Employees: 430
• Year Founded: 2000

Price Target and Rating

• Average Price Target for MacroGenics: $3.60
• High Price Target: $5.00
• Low Price Target: $2.00
• Potential Upside/Downside: +116.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$66.97 million
• Net Margins: -21.99%
• Pretax Margin: -21.36%
• Return on Equity: -40.24%
• Return on Assets: -14.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.26
• Quick Ratio: 5.02

Sales & Book Value

• Annual Sales: $149.96 million
• Price / Sales: 0.70
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.85 per share
• Price / Book: 0.90

Miscellaneous

• Outstanding Shares: 63,210,000
• Free Float: 54,989,000
• Market Cap: $104.93 million
• Optionable: Optionable
• Beta: 1.63